Display options
Cite
Alfonso Y, Monzote L. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. Open Med Chem J. 2011;5:40-50doi: 10.2174/1874104501105010040.
Alfonso, Y., & Monzote, L. (2011). HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. The open medicinal chemistry journal, 540-50. https://doi.org/10.2174/1874104501105010040
Alfonso, Yenisey, and Monzote, Lianet. "HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites." The open medicinal chemistry journal vol. 5 (2011): 40-50. doi: https://doi.org/10.2174/1874104501105010040
Alfonso Y, Monzote L. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites. Open Med Chem J. 2011;5:40-50. doi: 10.2174/1874104501105010040. Epub 2011 Mar 09. PMID: 21629510; PMCID: PMC3103880.
Copy Download .nbib Format: NLM
Share it on

Open Med Chem J. 2011;5:40-50. doi: 10.2174/1874104501105010040. Epub 2011 Mar 09.

HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

The open medicinal chemistry journal

Yenisey Alfonso, Lianet Monzote

Affiliations

  1. Parasitology Department, Institute of Tropical Medicine "Pedro Kourí", Cuba.

PMID: 21629510 PMCID: PMC3103880 DOI: 10.2174/1874104501105010040

Abstract

The impact of highly active antiretroviral therapy (HAART) in the natural history of AIDS disease has been allowed to prolong the survival of people with HIV infection, particularly whose with increased HIV viral load. Additionally, the antiretroviral therapy could exert a certain degree of protection against parasitic diseases. A number of studies have been evidenced a decrease in the incidence of opportunistic parasitic infections in the era of HAART. Although these changes have been attributed to the restoration of cell-mediated immunity, induced by either non-nucleoside reverse transcriptase inhibitors or HIV protease inhibitors, in combination with at least two nucleoside reverse transcriptase inhibitors included in HAART, there are evidence that the control of these parasitic infections in HIV-positive persons under HAART, is also induced by the inhibition of the proteases of the parasites. This review focuses on the principal available data related with therapeutic HIV-protease inhibitors and their in vitro and in vivo effects on the opportunistic protozoan parasites.

Keywords: Protease inhibitors; antiretrovirals; parasite; protozoa; therapeutic agents

References

  1. J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S91-4 - PubMed
  2. Lancet. 1998 Jan 24;351(9098):256-61 - PubMed
  3. Clin Pharmacokinet. 1998 Mar;34(3):189-201 - PubMed
  4. JAMA. 1997 Jan 8;277(2):145-53 - PubMed
  5. J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):458-61 - PubMed
  6. J Antimicrob Chemother. 2003 Sep;52(3):359-64 - PubMed
  7. Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):285-300 - PubMed
  8. Drugs. 2004;64(18):2101-24 - PubMed
  9. Antimicrob Agents Chemother. 2005 Jul;49(7):2983-5 - PubMed
  10. Expert Opin Pharmacother. 2001 Feb;2(2):303-15 - PubMed
  11. Parasite Immunol. 2007 Feb;29(2):57-71 - PubMed
  12. J Parasitol. 1997 Aug;83(4):771-4 - PubMed
  13. Lancet. 2003 Sep 27;362(9389):1008-9 - PubMed
  14. Curr Opin Microbiol. 2004 Aug;7(4):375-81 - PubMed
  15. J Acquir Immune Defic Syndr. 2004 Sep 1;37(1):1111-24 - PubMed
  16. Expert Opin Drug Saf. 2003 Nov;2(6):529-41 - PubMed
  17. Curr Opin Investig Drugs. 2009 Aug;10(8):775-86 - PubMed
  18. Drugs. 2009;69(4):477-503 - PubMed
  19. Antimicrob Agents Chemother. 2008 Jul;52(7):2653-6 - PubMed
  20. Clin Microbiol Infect. 2002 Oct;8(10):634-40 - PubMed
  21. Int J Antimicrob Agents. 2007 Jan;29(1):98-102 - PubMed
  22. Trends Parasitol. 2005 Feb;21(2):58-63 - PubMed
  23. Trends Parasitol. 2001 Nov;17(11):532-7 - PubMed
  24. Curr Infect Dis Rep. 2000 Aug;2(4):358-362 - PubMed
  25. AIDS. 2004 Apr 30;18(7):1051-9 - PubMed
  26. Drugs. 2000 Dec;60(6):1383-410 - PubMed
  27. J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):174-80 - PubMed
  28. N Engl J Med. 1998 Mar 26;338(13):853-60 - PubMed
  29. Exp Parasitol. 2009 Oct;123(2):122-7 - PubMed
  30. Int J Parasitol. 2003 Jul;33(7):757-64 - PubMed
  31. Cell Res. 2003 Aug;13(4):239-49 - PubMed
  32. Infect Immun. 1999 Feb;67(2):844-52 - PubMed
  33. JAMA. 1989 Jan 27;261(4):571-6 - PubMed
  34. Ann Intern Med. 2000 Jul 4;133(1):35-9 - PubMed
  35. Int J Epidemiol. 2002 Oct;31(5):951-8 - PubMed
  36. J Parasitol. 1996 Aug;82(4):638-40 - PubMed
  37. Lancet. 2005 Jan 15-21;365(9455):233-40 - PubMed
  38. Lancet. 2001 Feb 24;357(9256):592-8 - PubMed
  39. Antiviral Res. 2010 Jan;85(1):59-74 - PubMed
  40. Expert Opin Pharmacother. 2009 Jul;10(10):1615-29 - PubMed
  41. Bull World Health Organ. 1999;77(8):624-40 - PubMed
  42. Ther Clin Risk Manag. 2009 Feb;5(1):99-116 - PubMed
  43. J Acquir Immune Defic Syndr. 2001 Sep 1;28(1):9-13 - PubMed
  44. Drugs. 2005;65(15):2209-44 - PubMed
  45. Antimicrob Agents Chemother. 2007 Feb;51(2):759-62 - PubMed
  46. Nat Med. 2008 Jul;14(7):762-6 - PubMed
  47. Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28 - PubMed
  48. Clin Ther. 2000 May;22(5):549-72 - PubMed
  49. Eur J Clin Microbiol Infect Dis. 2000 Mar;19(3):213-7 - PubMed
  50. PLoS One. 2009;4(3):e4918 - PubMed
  51. HIV Clin Trials. 2006 Nov-Dec;7(6):285-90 - PubMed
  52. AIDS. 2004 Feb 20;18(3):547-54 - PubMed
  53. Clin Pharmacokinet. 1998 Oct;35(4):275-91 - PubMed
  54. J Parasitol. 1996 Dec;82(6):889-92 - PubMed
  55. Drugs. 1998 Jul;56(1):147-67 - PubMed
  56. Drugs. 2003;63(8):769-802 - PubMed
  57. AIDS Patient Care STDS. 2003 Nov;17(11):551-64 - PubMed
  58. Int J Antimicrob Agents. 2005 Jul;26(1):92-4 - PubMed
  59. Crit Rev Biochem Mol Biol. 2003;38(2):89-119 - PubMed
  60. Antimicrob Agents Chemother. 2006 Feb;50(2):639-48 - PubMed
  61. Curr Med Chem. 2007;14(26):2734-48 - PubMed
  62. Genome Res. 2003 Apr;13(4):601-16 - PubMed
  63. Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):990-5 - PubMed
  64. Antimicrob Agents Chemother. 2000 Sep;44(9):2575-7 - PubMed
  65. J Infect Dis. 2009 Jan 1;199(1):134-41 - PubMed
  66. Ann Trop Med Parasitol. 2003 Oct;97 Suppl 1:3-15 - PubMed
  67. Adv Parasitol. 1999;43:105-59 - PubMed
  68. Clin Infect Dis. 2008 Mar 1;46(5):719-25 - PubMed
  69. Expert Opin Pharmacother. 2007 Apr;8(6):839-50 - PubMed
  70. Curr Opin Neurol. 2006 Aug;19(4):358-61 - PubMed
  71. Lancet. 2003 Sep 27;362(9389):1039-41 - PubMed
  72. Gastroenterol Clin North Am. 1996 Sep;25(3):493-515 - PubMed
  73. J Infect Dis. 2008 Nov 1;198(9):1292-9 - PubMed
  74. Parassitologia. 2004 Jun;46(1-2):95-9 - PubMed
  75. Curr Opin Infect Dis. 2007 Feb;20(1):3-10 - PubMed
  76. Pharmacotherapy. 2006 Aug;26(8):1111-33 - PubMed
  77. N Engl J Med. 1998 Apr 30;338(18):1281-92 - PubMed
  78. Chem Rev. 2002 Dec;102(12):4431-58 - PubMed
  79. Drug Metab Dispos. 1995 Feb;23(2):266-70 - PubMed
  80. Am J Gastroenterol. 2000 Feb;95(2):457-62 - PubMed
  81. Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):347-61 - PubMed
  82. Clin Pharmacokinet. 2006;45(2):137-68 - PubMed
  83. Mol Biochem Parasitol. 1999 Sep 20;103(1):49-60 - PubMed
  84. Sex Transm Dis. 1999 Apr;26(4 Suppl):S2-7 - PubMed
  85. Mol Biochem Parasitol. 2003 Nov;132(1):1-16 - PubMed
  86. Int J Antimicrob Agents. 2009 Apr;33(4):307-20 - PubMed
  87. Traffic. 2007 Aug;8(8):1018-34 - PubMed
  88. Lancet. 2004 Jun 12;363(9425):1965-76 - PubMed
  89. J Infect Dis. 2004 Dec 1;190(11):1998-2000 - PubMed
  90. Trends Parasitol. 2001 Oct;17(10):491-8 - PubMed

Publication Types